Back to Quality Research
COOThe Cooper Companies, Inc
Health Care · Health Care Supplies · Large
$61.21−0.71%
As of 23 Oct 2026Mkt cap $13.6B
Stage 13
WATCH
Fundamentals
47.4/75
Technical
6.3/15
Independent
53.7/90
GCAE viewbusiness is credible but technical recovery is not yet actionable
Price
- 1M
- +10.5%
- 3M
- −12.9%
- 6M
- −5.0%
- 1Y
- −17.8%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 51.9xHist median 41.1x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 21.5x
- FCF yield
- 4.7%
Quality
- ROIC
- 4.3%
- Operating margin
- 16.7%
- FCF margin
- 10.6%
- Current ratio
- 1.9x
Growth
- Revenue growth
- +5.1%Latest FY YoY
- Revenue CAGR
- +8.8%
- EPS CAGR
- −40.4%
- FCF CAGR
- −4.6%
Capital
- Share-count trend
- +0.2%3Y annualised
- Net debt
- $2.3B2.9x OCF
Annual trend
- CAGR 2021–2025
- +8.8%
- Latest · 2025
- $4B
- YoY
- +5.1%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
business is credible but technical recovery is not yet actionable
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-12-10
More details & evidence
Production decision
- Stage 13
- WATCH
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded